NCT04735627Recruiting
Real-Time Levodopa Level Monitoring in Parkinson Disease
Real-Time Levodopa Monitoring for Improved Management of Parkinson Disease
Source: ClinicalTrials.gov · Last updated 11 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This project aims to develop a minimally invasive sensor device to monitor levodopa levels in real time. We will test the accuracy, tolerability, and safety of this device in people with Parkinson disease.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 19 Sept 2020
- Start date
- 7 Dec 2021
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of California, San Diego
- Diseases
- Parkinson disease
- NCT number
- NCT04735627
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 7 Dec 2021 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Other neurological conditions including but not limited to stroke, dementia (including Parkinson disease dementia), or traumatic brain injury
- Co-existent major psychiatric disease
- Uncontrolled, active medical conditions (e.g., heart, kidney, or liver failure, diabetes, etc.)
- Any other condition, that in the opinion of the investigators, would place the participant at risk.
Other
- Status post deep brain stimulation (DBS) device placement
Who the study is looking for
- Participants must meet the Movement Disorders Society (MDS) diagnostic criteria for clinically established Parkinson disease.
- Able to provide signed informed consent (in English or Spanish)
- Mild, moderate, or severe Parkinson disease, able to ambulate (Hoehn and Yahr stages I-IV)
- Taking instant release oral carbidopa/levodopa therapy
- Either not taking, or on stable doses of any of the following antiparkinsonian medications: dopamine agonists, monoamine oxidase B (MAO-B) inhibitors or catecholamine O-methyl transferase (COMT) inhibitors
Age in the registry: 40 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Diego Coordinator of this site? Confirm its status | San Diego | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.